|
|
Thomas Singer
First name and surname Thomas Singer Date of birth April 4, 1960 Place of birth Schwandorf Nationality German
Education
1978
|
Study of Biotechnology Science, University of Munich, Weihenstephan |
| 1982 |
Dipl. Ing. agr. (M.Sc.) |
1983-1988
|
Faculty of Veterinary Medicine Ludwig-Maximilian University of Munich (D.V.M.) |
1989
|
Ph.D. thesis: Deoxyspergualin, a New Immunosuppressive Regimen in Xenogeneic Organ Transplantation (Dr. med. vet.) |
1993
|
Veterinary Board Certification for Toxicology (FVH, Spezialtierarzt für Grundlagenmedizin und Toxikologie, CH) |
| 1994 |
Certified Diplomate of the American Board of Toxicology, DABT |
1996
|
Veterinary Board Certification for Pharmacology and Toxicology (Fachtierarzt für Pharmakologie und Toxikologie)
|
| 2003 |
Fellow Pembroke College, Cambridge, UK |
Employment history
2004
|
Global Deputy Head Non Clinical Development Roche Pharma AG (TRD small and macro molecules) |
2004
|
Head of the Roche Holding Biotherapeutic Workgroup. Scope early development of biotherapeutics with regard to safety, regulatory and API. Development of company holding wide guidelines to harmonize protein development within the Roche Holding (Roche, Chugai, Genentech) according to the most current regulatory standards and impacting health authority regulations. |
| 2003 |
Appointment to Senior Vice President |
| 1999 - 2003 |
European Liaison Officer of the American Board of Toxicology
|
| 2002 |
Global Head of Non Clinical Safety at F. Hoffmann-La Roche Ltd., Basel |
| 2000 |
Chair of the Boehringer Ingelheim Safety Committee |
1998
|
Head of Department of Nonclinical Drug Safety at Boehringer Ingelheim Pharma KG, Biberach
|
| 1997 |
Scientific Deputy Head of the Department TOX/PATH Novartis AG |
| 1996 |
Member of Integration Team Drug Safety Sandoz/Ciba to form Novartis |
| 1995 |
Deputy Head of Toxicology, Sandoz Pharma Ltd. |
1992
|
Head of General Toxicology, Sandoz. Pharma Ltd., Department of Drug Safety. |
| 1989 |
Sandoz Pharma Ltd., Department of Drug Safety | Membership of Roche Management Boards
RDC - Research and Development Committee Chair J. Knowles, member of the Roche Executive Committee and Head of Global Research Permanent and full membership since 2002
LCC - Life Cycle Committee Chair W. Burns, CEO Division Roche Pharmaceuticals Scope Late Stage Development and Marketing Ad hoc membership since 2002
DSC - Drug Safety Committee Chair E. Holdener, Head Global Pharmaceutical Drug Development Full membership since 2002
NC - DSC - Non Clinical - Drug Safety Committee Chair and full member Scope Preclinical and Early Clinical Safety. Responsibility for Global Safety issues and for recommendations for dose level selections in the subsequent Phase I and Phase II clinical trials.
RMT - Research Management Team Chair J. Knowles Full membership since 2003
STS - Safety and Technical Science Management Team Co-Chair and full member since 2002
Scientific Review Board Roche Holding Chugai Japan, Palo Alto, Nutley, Basel, Penzberg Full member
TPI - Therapeutic Protein Initiative Full member and advisor
RMM - Roche Management Meeting Chair F. Humer, Chairman Roche Board of Directors. Full member since 2002. Contributions to Research and Development performance 11 NDA’s 88 IND/CTA’s 1 world wide patent
Awards 2 Roche Olympiad medals for the safety organization granted in March 2006 by W. Burns, CEO Pharmaceuticals Division Global Laboratory Information Management System Program (GLIMS)
Investigative Rat Toxicology Studies to elucidate the mechanism of peripheral neuropathy Memberships of scientific societies
• Society for Veterinary Pathology • Society of Toxicologic Pathologists (USA) • Deutsche Veterinärmedizinische Gesellschaft (DVG) • Fachgruppe Allgemeine Pathologie und Pathologische Anatomie • Eurotox member • Full Member of the Society of Toxicology (SOT) • European Liaison of the American Board of Toxicology • EFPIA Working Party Safety AHG • British Society of Toxicology
Pembroke College Cambridge William Pit Fellow
Thomas Singer - April 20th 2006
|